A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lenvatinib|DRUG: Pembrolizuma|DRUG: Fulvestrant
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Merck Sharp & Dohme LLC